My preference would be to sign up a deal with BP to take current formulation to market and let them tinker with adhesion/absorption properties of the delivery method going forward. This small company has enough on its plate already and a cash infusion from a B-OM deal would go a long way to delivering on the promise B-IBD indications, for instance, or any of the other options deemed to optimize opportunities already under patent.
News 
Market Data 
Discover 
